10 July 2026 – The Healthy Mothers Healthy Babies (HMHB) virtual Coffee & Chai Chat, held on 9 July 2026, brought together 215 researchers, policymakers, implementers, and development partners from around the world to explore Ethiopia’s journey from generating evidence on multiple micronutrient supplementation (MMS) to scaling the intervention through national policy and programming. The session, titled “From Evidence to Action: Lessons from Ethiopia on Scaling MMS,” featured Dr. Masresha Tessema of the Ethiopian Public Health Institute (EPHI) and Dr. Ramadhani Noor of UNICEF Ethiopia.

VIEW THE SLIDES: Masresha Tessema |  Ramadhani Noor

Questions and Answers from the Chat

REGISTER FOR FUTURE CHATS

Watch the Recording

Key Messages

Masresha Tessema (Ethiopia Public Health Institute)

Evidence and Trial Findings

  • Ethiopia faces multiple micronutrient deficiencies, including deficiencies in zinc, folate, vitamin A, and vitamin D, alongside high rates of low birth weight and stunting.
  • Global evidence suggests that MMS is more effective than IFA alone, but Ethiopia required country-specific evidence before policy adoption.
  • Ethiopia conducted one of Africa’s largest MMS effectiveness trials, enrolling over 85,000 pregnant women across five regions and approximately 100 health facilities.

Key Results

  • Women receiving MMS had infants with an average birth weight increase of approximately 38 grams compared with those receiving IFA.
  • MMS was associated with an estimated 27% reduction in low birth weight compared with IFA.
  • Adherence was substantially higher in the MMS group, with 85% of women taking supplements for at least 90 days, compared with 53% in the IFA group.
  • A clear dose-response relationship was observed: women who consumed MMS for at least 90 days experienced even greater birth weight gains (approximately 58–60 grams).

Implementation Lessons

  • Government ownership and engagement at all administrative levels were critical for successful implementation.
  • Strong coordination between implementers, researchers, donors, and government stakeholders facilitated success.
  • Strengthening routine health information systems and health worker capacity improved data quality and implementation effectiveness.

Scale-Up Considerations

  • Future success depends on increasing effective coverage, improving early ANC attendance, addressing cultural barriers, and leveraging routine health data.
  • Sustainability will require local production of MMS and continued program support.
  • MMS has demonstrated a favorable return on investment and is cost-effective despite higher commodity costs than IFA.

 

Ramadhani Noor (UNICEF Ethiopia)

From Evidence to Policy

  • Ethiopia’s transition to MMS scale-up was driven by a high burden of maternal undernutrition, anemia, low birth weight, and neural tube defects, combined with the availability of strong local evidence.
  • The Ethiopian government officially transitioned to MMS scale-up policy in December following the demonstration program and research findings.

Program Design

  • MMS introduction was intentionally used as an entry point to strengthen the entire antenatal care (ANC) platform rather than simply replacing IFA tablets.
  • The program focused on demand generation, improving service quality, increasing ANC attendance, strengthening adherence, and enhancing maternal nutrition services.

Social and Behavioral Strategies

  • Social and behavior change interventions were central to success.
  • Behavioral research through the Addis Ababa University Behavioral Insights Design Lab identified local barriers and developed context-specific solutions.
  • Monthly pregnant women conferences and peer support mechanisms proved especially effective in improving adherence and ANC engagement.

Social Marketing and Local Market Development

  • Ethiopia tested social marketing approaches with Marie Stopes International to reach women receiving care in private health facilities.
  • Partnerships with manufacturers such as Renata Bangladesh helped establish a pathway for commercialization and supply.

Additional Findings

  • Approximately 633,000 women have been reached through the demonstration and scale-up phases combined.
  • MMS implementation districts showed improvements in:
    • Early ANC attendance
    • Hemoglobin testing
    • Nutrition counseling quality
    • Supplement uptake
    • Postnatal care utilization
  • Young women, rural women, and less educated women demonstrated lower adherence, highlighting important equity gaps that require targeted interventions.

Policy and Financing

  • Local evidence informed Ministry of Health policy briefs, interim national guidance, and Ethiopia’s MMS transition roadmap.
  • Ethiopia developed a costed roadmap estimating US$63.5 million to achieve national scale-up by 2030, with roughly 70% allocated to commodity costs.
  • The roadmap supports expansion into approximately 200 new districts annually through 2030.

Conclusion

  • Ethiopia’s landmark MMS trial involving more than 85,000 pregnant women demonstrated that MMS improved birth outcomes compared with iron-folic acid (IFA) supplementation, increasing average birthweight by approximately 38 grams and reducing low birthweight by about 27%. Women who consumed at least 90 tablets experienced even greater benefits, with an average birthweight increase of about 58 grams.
  • Adherence matters. The study showed a clear dose-response relationship, with higher adherence resulting in greater impact. At least 85% of women in the MMS arm adhered to supplementation for 90 days or more, compared with 53% in the IFA arm, highlighting the importance of early ANC attendance, counselling, and continuous access to supplements.
  • MMS served as a catalyst for strengthening antenatal care services. Districts implementing MMS reported improvements in early ANC attendance, nutrition counselling, hemoglobin testing, follow-up visits, and overall utilization of maternal health services, demonstrating that MMS introduction can strengthen health systems beyond supplementation alone.
  • Strong government leadership, local evidence, and multi-partner collaboration enabled Ethiopia to move rapidly from research to policy and implementation. Findings from the demonstration program informed national policy, implementation guidance, and a costed roadmap for nationwide MMS scale-up by 2030.
  • Social and behaviour change interventions were critical to improving uptake and adherence. Ethiopia used community engagement, pregnant mothers’ groups, peer support mechanisms, and tailored behaviour-change strategies to address barriers to ANC attendance and consistent supplement use.
  • Equity gaps remain. Young mothers, rural women, and less educated women require targeted support to ensure equitable program impact.
  • MMS is cost-effective despite higher commodity costs, offering substantial health returns and supporting long-term maternal and newborn health outcomes.
  • A clear roadmap accelerates scale-up. Ethiopia moved from evidence generation to national policy and a fully costed scale-up plan within approximately five years.
  • Sustainable financing and local production are key priorities for the next phase of scale-up. Ethiopia has developed an investment case and financing strategy, while also exploring local manufacturing to reduce costs and support long-term sustainability.
  • Ethiopia’s experience offers a practical model for other countries seeking to scale MMS. The key lesson is that successful scale-up requires more than an effective product—it depends on strong health systems, reliable supply chains, routine data systems, sustainable financing, and government ownership to translate evidence into impact at scale.

Moderated by Dr. Martin Mwangi, HMHB Program Lead, the session concluded with reflections on Ethiopia’s broader contribution to global MMS scale-up efforts. Speakers noted that the country’s experience provides a practical framework for translating evidence into policy and then into large-scale implementation. As more countries consider transitioning from IFA to MMS, Ethiopia’s journey offers valuable lessons on leveraging routine health systems, strengthening ANC platforms, building sustainable financing mechanisms, and maintaining strong government ownership throughout the process. The webinar reinforced a clear message: MMS has the potential to improve maternal and newborn outcomes, but successful scale-up depends on much more than the supplement itself. Strong health systems, reliable supply chains, behavior change programming, sustainable financing, routine data systems, and committed national leadership are all essential to translating evidence into impact at scale.

Stay Informed

Get the latest news about HMHB, MMS, BEP, and news from the world of maternal nutrition.

Country